Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, ...
BioXcel Therapeutics strengthens cash position to advance SERENITY trial
BioXcel Therapeutics (BTAI) announced that, following the successful raise of $14 million gross proceeds in an equity financing that closed on ...
BioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trial
BioXcel Therapeutics (BTAI) announced it has reached 33% enrollment in its 200-patient SERENITY At-Home trial. The Phase 3 trial is designed to ...
BioXcel Shares Are Up Today: What's Going On?
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares are trading higher Monday following news that the U.S. Food and Drug ...
BioXcel Therapeutics (BTAI) Projected to Post Earnings on Tuesday
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect BioXcel Therapeutics to ...
BioXcel Therapeutics Climbs After Enrollment Update in Drug Trial
BioXcel said the Phase 3 trial is designed to evaluate the safety of BXCL501. The trial's topline-data results, which are expected in the second half of 2025, are intended to support a potential ...
Nasdaq6d
BioXcel Therapeutics Reports 33% Enrollment in SERENITY At-Home Trial for IGALMI® Label Expansion, Topline Data Expected in 2025
BioXcel Therapeutics announces 33% enrollment in SERENITY At-Home trial evaluating BXCL501 for agitation treatment, with data expected mid-2025. BioXcel Therapeutics announced that it has achieved ...